RECOVER-ENERGIZE Platform Protocol

Inclusion Criteria:

1. ≥ 18 years of age at the time of enrollment

2. Previous suspected, probable, or confirmed SARS-CoV-2 infection, as defined by thePan American Health Organization*

• Suspected* or probable SARS-CoV-2 infection will only be allowed if it occurredbefore May 1, 2021, and will be limited to no more than 10% of the studypopulation. Otherwise, confirmed cases are required. Suspected case of SARS-CoV-2 infection - Three options, A through C: A. A person who meets the clinical OR epidemiological criteria. Clinical criteria:Acute onset of fever AND cough (influenza-like illness) OR Acute onset of ANY THREEOR MORE of the following signs or symptoms: fever, cough, general, weakness/fatigue,headache, myalgia, sore throat, coryza, dyspnea, nausea, diarrhea, anorexia.Epidemiological criteria: Contact of a probable or confirmed case or linked to aCOVID-19 cluster; or B. Acute respiratory infection with history of fever ormeasured fever of ≥ 38°C; and cough; with onset within the last 10 days; and whorequires hospitalization; or C. With no clinical signs or symptoms, NOR meetingepidemiologic criteria with a positive professional use or self-test SARS-CoV-2Antigen-Rapid Diagnostic Test. Probable case of SARS-CoV-2 infection: A. A patient who meets clinical criteria above AND is a contact of a probable orconfirmed case or is linked to a COVID-19 cluster. Confirmed case of SARS-CoV-2 infection - Two options, A and B: A. A person with a positive nucleic acid amplification test, regardless of clinicalcriteria OR epidemiological criteria; or B. Meeting clinical criteria AND/ORepidemiological criteria (See suspected case A above for criteria). With a positiveprofessional use or self-test SARS- CoV-2 Antigen-Rapid Diagnostic Test.

3. Self-reported limitation to physical activity due to the presence of symptoms suchas fatigue, shortness of breath, and/or PEM following a SARS-CoV-2 infection, thathas persisted for at least 12 weeks and is present at the time of consent.

4. Willing, able, and agree to provide informed consent, complete questionnaires andoutcome assessments, and participate in the study, including assigned interventionor control and study visits whether remote, hybrid, or in-person.

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation in this study:

1. Known active acute SARS-CoV-2 infection ≤ 4 weeks prior to the consent.

2. Known prior diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), not related to SARS-CoV-2 infection.

3. Current or recent use (within the last 14 days) of a formal program utilizing one ormore of the current study intervention(s) or similar intervention(s) to treat theunderlying condition, unless a washout period is permitted per Appendices.

4. Participation in another interventional clinical trial.

5. Any condition that would make the participant, in the opinion of the investigator,unsuitable for the study.